Skip to main content

Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature.

Publication ,  Journal Article
Katz-Greenberg, G; Ghimire, S; Zhan, T; Mallari, K; Whitaker-Menezes, D; Gong, J; Uppal, G; Martinez-Outschoorn, U; Martinez Cantarin, MP
Published in: Am J Cancer Res
2021

Post-transplant lymphoproliferative disorders (PTLD) are among the most serious complications after solid organ transplantation (SOT). Monomorphic diffuse large B-cell lymphoma (DLBCL) is the most common subtype of PTLD. Historically, outcomes of PTLD have been poor with high mortality rates and allograft loss, although this has improved in the last 10 years. Most of our understanding about PTLD DLBCL is extrapolated from studies in non-PTLD DLBCL, and while several clinical factors have been identified and validated for predicting non-PTLD DLBCL outcomes, the molecular profile of PTLD DLBCL has not yet been characterized. Compartment-specific metabolic reprograming has been described in non-PTLD DLBCL with a lactate uptake metabolic phenotype with high monocarboxylate transporter 1 (MCT1) expression associated with worse outcomes. The aim of our study was to compare the outcomes of PTLD in our transplant center to historic cohorts, as well as study a subgroup of our PTLD DLBCL tumors and compare metabolic profiles with non-PTLD DLBCL. We performed a retrospective single institution study of all adult patients who underwent a SOT between the years 1992-2018, who were later diagnosed with PTLD. All available clinical information was extracted from the patients' medical records. Tumor metabolic markers were studied in a subgroup of PTLD DLBCL and compared to a group of non-PTLD DLBCL. Thirty patients were diagnosed with PTLD following SOT in our center. Median time from SOT to PTLD diagnosis was 62.8 months (IQR 7.6; 134.4), with 37% of patients diagnosed with early PTLD, and 63% with late PTLD. The most common PTLD subtype was DLBCL. Most patients were treated with reduction of their immunosuppression (RIS) including a group who were switched from calcineurin inhibitor (CNI) to mTOR inhibitor based IS, in conjunction with standard anti-lymphoma chemoimmunotherapy. Progression free survival of the PTLD DLBCL cohort was calculated at 86% at 1 year, and 77% at 3 and 5-years, with overall survival of 86% at 1 and 3-years, and 75% at 5 years. Death censored allograft survival in the kidney cohort was 100% at 1 year, and 93% at 3, 5 and 10 years. MCT1 H scores were significantly higher in a subset of the non-PTLD DLBCL patients than in a PTLD DLBCL cohort. Our data is concordant with improved PTLD outcomes in the last 10 years. mTOR inhibitors could be an alternative to CNI as a RIS strategy. Finally, PTLD DLBCL may have a distinct metabolic profile with reduced MCT1 expression compared to non-PTLD DLBCL, but further studies are needed to corroborate our limited cohort findings and to determine if a specific metabolic profile is associated with outcomes.

Duke Scholars

Published In

Am J Cancer Res

ISSN

2156-6976

Publication Date

2021

Volume

11

Issue

9

Start / End Page

4624 / 4637

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Katz-Greenberg, G., Ghimire, S., Zhan, T., Mallari, K., Whitaker-Menezes, D., Gong, J., … Martinez Cantarin, M. P. (2021). Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature. Am J Cancer Res, 11(9), 4624–4637.
Katz-Greenberg, Goni, Sushil Ghimire, Tinging Zhan, Kashka Mallari, Diana Whitaker-Menezes, Jerald Gong, Guldeep Uppal, Ubaldo Martinez-Outschoorn, and Maria P. Martinez Cantarin. “Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature.Am J Cancer Res 11, no. 9 (2021): 4624–37.
Katz-Greenberg G, Ghimire S, Zhan T, Mallari K, Whitaker-Menezes D, Gong J, et al. Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature. Am J Cancer Res. 2021;11(9):4624–37.
Katz-Greenberg G, Ghimire S, Zhan T, Mallari K, Whitaker-Menezes D, Gong J, Uppal G, Martinez-Outschoorn U, Martinez Cantarin MP. Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature. Am J Cancer Res. 2021;11(9):4624–4637.

Published In

Am J Cancer Res

ISSN

2156-6976

Publication Date

2021

Volume

11

Issue

9

Start / End Page

4624 / 4637

Location

United States

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis